Mark Holodniy

Publications

• Concurrent outbreaks with co-infection of norovirus and Clostridium difficile in a long-term-care facility. Ludwig A, Sato K, Schirmer P, Maniar A, Lucero-Obusan C, Fleming C, Ryono R, Oda G, Winters M, Holodniy M. Epidemiol Infect. 2013: 1-6
• Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. PLoS One. 2013; 8 (3): e58975
• Dengue surveillance in Veterans Affairs healthcare facilities, 2007-2010. Schirmer PL, Lucero-Obusan CA, Benoit SR, Santiago LM, Stanek D, Dey A, Martinez M, Oda G, Holodniy M. PLoS Negl Trop Dis. 2013; 7 (3): e2040
• Health-related Quality of Life Assessment after Antiretroviral Therapy: A Review of the Literature. Gakhar H, Kamali A, Holodniy M. Drugs. 2013
• Immune Biomarker Differences and Changes Comparing HCV Mono-Infected, HIV/HCV Co-Infected, and HCV Spontaneously Cleared Patients. Kushner LE, Wendelboe AM, Lazzeroni LC, Chary A, Winters MA, Osinusi A, Kottilil S, Polis MA, Holodniy M. PLoS One. 2013; 8 (4): e60387
• Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Hou N, Owens DK, Desai M. PLoS One. 2013; 8 (3): e59551
• Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster. Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW. J Infect Dis. 2013
• Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial. Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Kyriakides TC, Cameron DW, Youle M, Sculpher M, Anis AH, Owens DK. Med Decis Making. 2012 Jan-Feb; 32 (1): 70-82
• Comparative assessment of antimicrobial usage measures in the Department of Veterans Affairs. Schirmer PL, Mercier RC, Ryono RA, Nguyen N, Lucero CA, Oda G, Holodniy M. Infect Control Hosp Epidemiol. 2012; 33 (4): 409-11
• Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. PLoS One. 2012; 7 (9): e45176
• Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. Winters MA, Lloyd RM, Shafer RW, Kozal MJ, Miller MD, Holodniy M. PLoS One. 2012; 7 (7): e40514
• IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. Osinusi A, Chary A, Winters MA, Naggie S, Masur H, Polis MA, Kottilil S, Holodniy M. J Med Virol. 2012; 84 (10): 1522-7
• New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. Ann Intern Med. 2012; 156 (4): 279-90
• Outcomes associated with a cognitive-behavioral chronic pain management program implemented in three public HIV primary care clinics. Trafton JA, Sorrell JT, Holodniy M, Pierson H, Link P, Combs A, Israelski D. J Behav Health Serv Res. 2012; 39 (2): 158-73
• Predictive value of HIV-1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment-experienced patients. Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, Holodniy M. HIV Med. 2012; 13 (6): 345-51
• Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection. Chary A, Winters MA, Eisen R, Knight TH, Asmuth DM, Holodniy M. J Med Virol. 2012; 84 (3): 431-7
• Results from a large-scale epidemiologic look-back investigation of improperly reprocessed endoscopy equipment. Holodniy M, Oda G, Schirmer PL, Lucero CA, Khudyakov YE, Xia G, Lin Y, Valdiserri R, Duncan WE, Davey VJ, Cross GM. Infect Control Hosp Epidemiol. 2012; 33 (7): 649-56
• Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Flaherty P, Natsoulis G, Muralidharan O, Winters M, Buenrostro J, Bell J, Brown S, Holodniy M, Zhang N, Ji HP. Nucleic Acids Res. 2012; 40 (1): e2
• Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Yiu P, Nguyen NN, Holodniy M. Pharmacotherapy. 2011; 31 (5): 480-9
• Determinants of the cost of health services used by veterans with HIV. Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin SC, Nosyk B, Holodniy M, Brown ST, Sculpher M, Anis AH, Owens DK. Med Care. 2011; 49 (9): 848-56
• Diagnosing invasive fungal disease in critically ill patients. Hsu JL, Ruoss SJ, Bower ND, Lin M, Holodniy M, Stevens DA. Crit Rev Microbiol. 2011; 37 (4): 277-312
• Enhanced health event detection and influenza surveillance using a joint Veterans Affairs and Department of Defense biosurveillance application. Lucero CA, Oda G, Cox K, Maldonado F, Lombardo J, Wojcik R, Holodniy M. BMC Med Inform Decis Mak. 2011: 11 56
• HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. Schirmer P, Winters M, Holodniy M. J Clin Virol. 2011; 52 (3): 261-4
• Interferon combination therapy for HIV/hepatitis C virus coinfection. Chary A, Holodniy M. Immunotherapy. 2011; 3 (9): 1087-102
• One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System. Hsu JL, Siroka AM, Smith MW, Holodniy M, Meduri GU. Int J Infect Dis. 2011; 15 (6): e382-7
• Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Piaseczny M, Russo J, Schechter M, Deyton L, Darbyshire J. PLoS One. 2011; 6 (3): e14764
• Use of dried clinical samples for storing and detecting influenza RNA. Winters M, Lloyd R, Shahidi A, Brown S, Holodniy M. Influenza Other Respi Viruses. 2011; 5 (6): 413-7
• An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). Dolor RJ, Ruybalid RL, Uyeda L, Edson RG, Phibbs C, Vertrees JE, Shih MC, Jacobson AK, Matchar DB. J Thromb Thrombolysis. 2010; 30 (3): 263-75
• Comparative effectiveness of dried plasma HIV-1 viral load testing in Brazil using ViveST for sample collection. Zanoni M, Cortes R, Diaz RS, Sucupira MC, Ferreira D, Inocencio LA, Vilhena C, Loveday C, Lloyd RM, Holodniy M. J Clin Virol. 2010; 49 (4): 245-8
• Connection domain mutations in treatment-experienced patients in the OPTIMA trial. Dau B, Ayers D, Singer J, Harrigan PR, Brown S, Kyriakides T, Cameron DW, Angus B, Holodniy M. J Acquir Immune Defic Syndr. 2010; 54 (2): 160-6
• Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh SS, Levin MJ, Harbecke RM, Oxman MN. J Am Geriatr Soc. 2010; 58 (9): 1634-41
• Effect of home testing of international normalized ratio on clinical events. Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, Vertrees JE, Shih MC, Holodniy M, Lavori P. N Engl J Med. 2010; 363 (17): 1608-20
• Effective detection of the 2009 H1N1 influenza pandemic in U.S. Veterans Affairs medical centers using a national electronic biosurveillance system. Schirmer P, Lucero C, Oda G, Lopez J, Holodniy M. PLoS One. 2010; 5 (3): e9533
• Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. Winters MA, Chary A, Eison R, Asmuth D, Holodniy M. J Med Virol. 2010; 82 (5): 791-8
• Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients. Chary A, Winters MA, Kottilil S, Murphy AA, Polis MA, Holodniy M. J Infect Dis. 2010; 202 (6): 889-93
• Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. McFall M, Saxon AJ, Malte CA, Chow B, Bailey S, Baker DG, Beckham JC, Boardman KD, Carmody TP, Joseph AM, Smith MW, Shih MC, Lu Y, Holodniy M, Lavori PW. JAMA. 2010; 304 (22): 2485-93
• Is spinal tuberculosis contagious? Schirmer P, Renault CA, Holodniy M. Int J Infect Dis. 2010; 14 (8): e659-66
• Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Winters MA, Van Rompay KK, Kashuba AD, Shulman NS, Holodniy M. Antimicrob Agents Chemother. 2010; 54 (10): 4059-63
• Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Chary A, Holodniy M. Rev Recent Clin Trials. 2010; 5 (3): 158-73
• Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. Palacios GC, Sanchez LM, Briones E, Ramirez TJ, Castillo H, Rivera LG, Vazquez CA, Rodriguez-Padilla C, Holodniy M. Int J Infect Dis. 2010; 14 (1): e34-40
• Sudden sensorineural hearing loss associated with vardenafil. Snodgrass AJ, Campbell HM, Mace DL, Faria VL, Swanson KM, Holodniy M. Pharmacotherapy. 2010; 30 (1): 112
• A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. Harbecke R, Oxman MN, Arnold BA, Ip C, Johnson GR, Levin MJ, Gelb LD, Schmader KE, Straus SE, Wang H, Wright PF, Pachucki CT, Gershon AA, Arbeit RD, Davis LE, Simberkoff MS, Weinberg A, Williams HM, Cheney C, Petrukhin L, Abraham KG, Shaw A, Manoff S, Antonello JM, Green T, Wang Y, Tan C, Keller PM. J Med Virol. 2009; 81 (7): 1310-22
• Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. Lloyd RM, Burns DA, Huong JT, Mathis RL, Winters MA, Tanner M, De La Rosa A, Yen-Lieberman B, Armstrong W, Taege A, McClernon DR, Wetshtein JL, Friedrich BM, Ferguson MR, O'Brien W, Feorino PM, Holodniy M. J Clin Microbiol. 2009; 47 (5): 1491-6
• Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study. Jamison RL, Shih MC, Humphries DE, Guarino PD, Kaufman JS, Goldfarb DS, Warren SR, Gaziano JM, Lavori P. Am J Kidney Dis. 2009; 53 (5): 779-89
• Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease Joyce, V, Barnett PG, Bayoumi A, Griffin SC, Kyriakides TC, Yu W, Sundaram V, Holodniy M, Brown ST, Cameron W,. Journal of Acquired Immune Deficiency Syndromes. 2009; 50 (1): 27-36
• Infectious complications in OIF/OEF veterans with traumatic brain injury. Dau B, Oda G, Holodniy M. J Rehabil Res Dev. 2009; 46 (6): 673-84
• Novel targets for antiretroviral therapy: clinical progress to date. Dau B, Holodniy M. Drugs. 2009; 69 (1): 31-50
• Oseltamivir for treatment and prophylaxis of influenza infection. Schirmer P, Holodniy M. Expert Opin Drug Saf. 2009; 8 (3): 357-71
• Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST. J Acquir Immune Defic Syndr. 2009; 51 (5): 631-9
• The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. Nosyk B, Sun H, Bansback N, Guh DP, Li X, Barnett P, Bayoumi A, Griffin S, Joyce V, Holodniy M, Owens DK, Anis AH. Qual Life Res. 2009; 18 (7): 815-24
• Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature. Raisch DW, Straight TM, Holodniy M. Pharmacotherapy. 2009; 29 (8): 988-92
• Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ. J Infect Dis. 2009; 200 (7): 1068-77
• Cost-effectiveness of HIV screening in patients older than 55 years of age. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Ann Intern Med. 2008; 148 (12): 889-903
• Frequency of HIV screening in the Veterans Health Administration: implications for early diagnosis of HIV infection. Valdiserri RO, Rodriguez F, Holodniy M. AIDS Educ Prev. 2008; 20 (3): 258-64
• HIV infection in the elderly Nguyen N, Holodniy M. Clinical Interventions in Aging. 2008; 3 (4): 1-20
• Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Holodniy M, Penzak SR, Straight TM, Davey RT, Lee KK, Goetz MB, Raisch DW, Cunningham F, Lin ET, Olivo N, Deyton LR. Antimicrob Agents Chemother. 2008; 52 (9): 3013-21
• Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S. J Interferon Cytokine Res. 2008; 28 (2): 89-100
• Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Louie JK, Kajon AE, Holodniy M, Guardia-LaBar L, Lee B, Petru AM, Hacker JK, Schnurr DP. Clin Infect Dis. 2008; 46 (3): 421-5
• The Relationship Between HIV Infection and Cardiovascular Disease. Dau B, Holodniy M. Curr Cardiol Rev. 2008; 4 (3): 203-18
• Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A. J Infect Dis. 2008; 197 (6): 825-35
• Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy. Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. HIV Clin Trials. 2007 Sep-Oct; 8 (5): 293-302
• A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E. Med Decis Making. 2007 Nov-Dec; 27 (6): 789-821
• Darunavir in the treatment of HIV-1 infection: a viewpoint by Mark Holodniy. Holodniy M, Drugs. 2007; 67 (18): 2803
• HIV testing of at risk patients in a large integrated health care system. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Tempio P, Holodniy M, Sanders GD, Shadle VM, McWhorter VC, Agoncillo T, Haren N, Chavis D, Borowsky LH, Yano EM, Jensen P, Simberkoff MS, Bozzette SA. J Gen Intern Med. 2007; 22 (3): 315-20
• Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Sanders GD, Taylor K, VanGroningen R, Shadle VM, McWhorter VC, Agoncillo T, Haren N, Nyland J, Tempio P, Khayr W, Dietzen DJ, Jensen P, Simberkoff MS, Bozzette SA, Holodniy M. Am J Public Health. 2007; 97 (12): 2173-8
• Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992-2004). Holodniy M, Hornberger J, Rapoport D, Robertus K, MaCurdy TE, Lopez J, Volberding P, Deyton L. J Acquir Immune Defic Syndr. 2007; 44 (1): 20-9
• Representational Fluency in HIV Clinical Practice: A Model of Instructor Discourse Banach, MA, Gifford, BR, Holodniy M. Journal of Continuing Education in the Health Professions. 2007; 27 (3): 149-156
• Role of Environmental Surveillance in Dtermining the Risk of Hospital-Acquired Legionellosis: A National Surveillance Study With Clinical Correlations Stout, JE, Muder RR, Mietzner S, Wagener MM, Perri MB, DeRoos K, Goodrich D, Arnold W, Williamson T, Ruark O, Treadway C, Eckstein EC, Marshall D, Rafferty ME, Sarro K, Page J, Jenkins R, Oda G, Shimoda KJ, Zervos MJ, Bittner M, Camhi SL, Panwalker AP, Donskey CJ, Nguyen MH, Holodniy M, Yu VL. Infection Control and Hospital Epidemiology. 2007; 28 (7): 818-824
• siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Liu Z, Winters M, Holodniy M, Dai H. Angew Chem Int Ed Engl. 2007; 46 (12): 2023-7
• Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet. Liu M, Holodniy M, Zolopa AR, Shafer RW. MedGenMed. 2006; 8 (1): 24
• HIV-1 load quantitation: a 17-year perspective. Holodniy M, J Infect Dis. 2006: 194 Suppl 1 S38-44
• Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus. Winters MA, Welles SL, Holodniy M. J Virol. 2006; 80 (8): 4196-9
• Prevention of shingles by varicella zoster virus vaccination. Holodniy M, Expert Rev Vaccines. 2006; 5 (4): 431-43
• The effect of diagnosis with HIV infection on health-related quality of Life. Honiden S, Sundaram V, Nease RF, Holodniy M, Lazzeroni LC, Zolopa A, Owens DK. Qual Life Res. 2006; 15 (1): 69-82
• The safety and tolerability of Z-100 in patients infected with HIV-1 Borucki M, Holodniy M, Pierone G, Ruane P, Steinhart C, Williams S, Slom T, Palella F, Hare CB, Yoshida Y, Li KD, Pollard RB. Antiviral Therapy. 2006: 11 297-303
• Utilization and access to antiretroviral genotypic resistance testing and results within the US Department of Veterans Affairs. Goetz MB, Holodniy M, Poulton JS, Rodriguez FH, Rigsby MO. J Acquir Immune Defic Syndr. 2006; 41 (1): 59-62
• Proteomic analysis of serum cytokine levels in response to highly active antiretroviral therapy (HAART). Relucio KI, Beernink HT, Chen D, Israelski DM, Kim R, Holodniy M. J Proteome Res. 2005 Mar-Apr; 4 (2): 227-31
• A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. N Engl J Med. 2005; 352 (22): 2271-84
• Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, Collier A, Conway B, Gulick RM, Holodniy M, Perno CF, Shafer RW, Richman DD, Wainberg MA, Kuritzkes DR. Clin Infect Dis. 2005; 41 (1): 92-9
• Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. Terrault, NA, Pawlotsky JM, McHutchison J, Anderson F, Krajden M, Gordon S, Zitron I, Perrillo R, Gish R, Holodniy M, Friesenhahn M.. Journal of Viral Hepatitis. 2005; 12 (5): 465-472
• Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. New England Journal of Medicine. 2005; 352 (6): 570-585
• Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. N Engl J Med. 2005; 352 (6): 570-85
• Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, Jortani SA, Kuramoto K, Ng V, Valdes R, Valsamakis A, Terrault NA. J Clin Microbiol. 2004; 42 (2): 563-9
• Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study. Holodniy M, Charlebois ED, Bangsberg DR, Zolopa AR, Schulte M, Moss AR. Int J STD AIDS. 2004; 15 (8): 543-51
• Accuracy of the TRUGENE HIV-1 genotyping kit. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd Jr RM, Reid C, Morgan GF, Winslow DL. J Clin Microbiol. 2003; 41 (4): 1586-93
• An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Kyriakides TC, Babiker A, Singer J, Cameron W, Schechter MT, Holodniy M, Brown ST, Youle M, Gazzard B. Control Clin Trials. 2003; 24 (4): 481-500
• High levels of adherence do not prevent accumulation of HIV drug resistance mutations. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. AIDS. 2003; 17 (13): 1925-32
• Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. Babik JM, Holodniy M. J Virol. 2003; 77 (3): 1940-50
• Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Chang TL, Chang CH, Simpson DA, Xu Q, Martin PK, Lagenaur LA, Schoolnik GK, Ho DD, Hillier SL, Holodniy M, Lewicki JA, Lee PP. Proc Natl Acad Sci U S A. 2003; 100 (20): 11672-7
• Role of Deoxyribonucleoside Kinases and Deoxyribonucleotide Pool Alterations in Nucleoside Reverse Transcriptase Inhibitor Induced Mitochondrial Toxicity Relucio K, Holodniy M. Curr. Med. Chem. - Anti-Infective Agents. 2003: 2 241-262
• Successful management of disseminated Nocardia transvalensis infection in a heart transplant recipient after development of sulfonamide resistance: case report and review. Lopez FA, Johnson F, Novosad DM, Beaman BL, Holodniy M. J Heart Lung Transplant. 2003; 22 (4): 492-7
• HIV-1 RNA and viral load. Relucio K, Holodniy M. Clin Lab Med. 2002; 22 (3): 593-610
• A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. Mole L, Schmidgall D, Holodniy M. J Acquir Immune Defic Syndr. 2001; 27 (3): 260-5
• Multinodular polymyositis in a patient with human immunodeficiency and hepatitis C virus coinfection. Richardson SJ, Lopez F, Rojas S, Cho S, Holodniy M, Herndier B, Katz J. Muscle Nerve. 2001; 24 (3): 433-7
• Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A. AIDS. 2000; 14 (4): 357-66
• Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system. Fujinaga M, Schulte M, Holodniy M. Teratology. 2000; 62 (2): 108-14
• HIV resistance testing--has it come of age? Holodniy M, AIDS Read. 2000; 10 (8): 474-5
• Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. Holodniy M, Rainen L, Herman S, Yen-Lieberman B. J Clin Microbiol. 2000; 38 (1): 323-6
• A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Holodniy M, Koch J, Mistal M, Schmidt JM, Khandwala A, Pennington JE, Porter SB. Am J Gastroenterol. 1999; 94 (11): 3267-73
• Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Mole L, Ockrim K, Holodniy M. Pharmacoeconomics. 1999; 16 (3): 307-15
• Effects of collection, processing, and storage on RNA detection and quantification. Holodniy M, Methods Mol Med. 1999: 26 43-59
• Viral Load Monitoring in HIV Infection. Holodniy M, Curr Infect Dis Rep. 1999; 1 (5): 497-503
• Controversies in AIDS treatment. Proceedings from CME conference sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Faculty roundtable discussion. Frost KR, Bellman P, Cohen CJ, Currier J, Dobkin J, El-Sadr W, Holodniy M, Leonard A, Merrick S, Pinsky L, Rubin DS, Saag M, Vaughn A. AIDS Patient Care STDS. 1998; 12 (7): 543-55
• Controversies in AIDS treatment. Proceedings from CME conference sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Question and answer session. Frost KR, Bellman P, Cohen CJ, Currier J, Dobkin J, El-Sadr W, Holodniy M, Leonard A, Merrick S, Pinsky L, Rubin D, Vaughn A, Saag M. AIDS Patient Care STDS. 1998; 12 (7): 557-66
• HIV quantitation in spiked vaginocervical secretions: lack of non-specific inhibitory factors. DATRI 005 Study Team. Division of AIDS Treatment Research Initiative. Holodniy M, Anderson D, Wright D, Sharma O, Cohn J, Alexander N, Stratton P, Reichelderferd P. J Virol Methods. 1998; 72 (2): 185-95
• Human immunodeficiency virus type 1 populations in blood and semen. Delwart EL, Mullins JI, Gupta P, Learn GH, Holodniy M, Katzenstein D, Walker BD, Singh MK. J Virol. 1998; 72 (1): 617-23
• Phenotypic and genotypic testing in clinical practice. Holodniy M, AIDS Patient Care STDS. 1998; 12 (7): 527-31
• Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays. Gingeras TR, Ghandour G, Wang E, Berno A, Small PM, Drobniewski F, Alland D, Desmond E, Holodniy M, Drenkow J. Genome Res. 1998; 8 (5): 435-48
• Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. Niu MT, Bethel J, Holodniy M, Standiford HC, Schnittman SM. J Infect Dis. 1998; 178 (1): 80-91
• HIV-1 protease inhibitors. A review for clinicians. Deeks SG, Smith M, Holodniy M, Kahn JO. JAMA. 1997; 277 (2): 145-53
• The impact of active herpes simplex virus infection on human immunodeficiency virus load. Mole L, Ripich S, Margolis D, Holodniy M. J Infect Dis. 1997; 176 (3): 766-70
• A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants. Owens DK, Holodniy M, McDonald TW, Scott J, Sonnad S. JAMA. 1996; 275 (17): 1342-8
• Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. Cohen OJ, Pantaleo G, Holodniy M, Fox CH, Orenstein JM, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT, Cohn J, Novak R, McMahon D, Bilello J, Fauci AS. J Infect Dis. 1996; 173 (4): 849-56
• Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay. Kline RL, McNairn D, Holodniy M, Mole L, Margolis D, Blattner W, Quinn TC. J Clin Microbiol. 1996; 34 (11): 2650-3
• HIV viral load markers in clinical practice. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. Nat Med. 1996; 2 (6): 625-9
• Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype. Holodniy M, Katzenstein D, Mole L, Winters M, Merigan T. J Infect Dis. 1996; 174 (4): 854-7
• Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design. Owens DK, Holodniy M, Garber AM, Scott J, Sonnad S, Moses L, Kinosian B, Schwartz JS. Ann Intern Med. 1996; 124 (9): 803-15
• Prescribing practice and cost of antibacterial prophylaxis for surgery at a US Veteran Affairs hospital. Ryono RA, Jones KS, Coleman RW, Holodniy M. Pharmacoeconomics. 1996; 10 (6): 630-43
• Quantitative relationship between platelet count and plasma virion HIV RNA. Holodniy M, Margolis D, Carroll R, Todd J, Mole L. AIDS. 1996; 10 (2): 232-3
• HIV viral load quantification, HIV resistance, and antiretroviral therapy. Katzenstein DA, Holodniy M. AIDS Clin Rev. 1995-1996: 277-303
• Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. Holodniy M, Mole L, Yen-Lieberman B, Margolis D, Starkey C, Carroll R, Spahlinger T, Todd J, Jackson JB. J Clin Microbiol. 1995; 33 (6): 1562-6
• Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT. Proc Natl Acad Sci U S A. 1995; 92 (13): 6017-21
• Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J, Eastman S. J Virol. 1995; 69 (6): 3510-6
• Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. Eastman PS, Boyer E, Mole L, Kolberg J, Urdea M, Holodniy M. J Clin Microbiol. 1995; 33 (10): 2777-80
• Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology. Todd J, Pachl C, White R, Yeghiazarian T, Johnson P, Taylor B, Holodniy M, Kern D, Hamren S, Chernoff D. J Acquir Immune Defic Syndr Hum Retrovirol. 1995: 10 Suppl 2 S35-44
• Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. Collier AC, Coombs RW, Katzenstein D, Holodniy M, Gibson J, Mordenti J, Izu AE, Duliege AM, Ammann AJ, Merigan T. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 (2): 150-6
• Antibiotic-associated pseudomembranous enteritis due to Clostridium difficile. Tsutaoka B, Hansen J, Johnson D, Holodniy M. Clin Infect Dis. 1994; 18 (6): 982-4
• Clinical application of reverse transcription-polymerase chain reaction for HIV infection. Holodniy M, Clin Lab Med. 1994; 14 (2): 335-49
• Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. Rasmussen L, Morris S, Wolitz R, Dowling A, Fessell J, Holodniy M, Merigan TC. J Infect Dis. 1994; 170 (3): 673-7
• Diurnal and short-term stability of HIV virus load as measured by gene amplification. Holodniy M, Mole L, Winters M, Merigan TC. J Acquir Immune Defic Syndr. 1994; 7 (4): 363-8
• Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in VACUTAINER CPT and standard VACUTAINER tubes. Mole L, Margolis D, Carroll R, Todd J, Holodniy M. J Clin Microbiol. 1994; 32 (9): 2212-5
• The use of pentoxifylline alone in HIV-infected patients. Mole L, Margolis D, Ghotbi L, Holodniy M. J Acquir Immune Defic Syndr. 1994; 7 (5): 519-21
• Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Merigan TC. J Infect Dis. 1993; 167 (4): 798-802
• Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. Holodniy M, Katzenstein D, Winters M, Montoya J, Shafer R, Kozal M, Ragni M, Merigan TC. J Acquir Immune Defic Syndr. 1993; 6 (4): 366-9
• Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect Montoya, JG, Wood R, Katzenstein D, Holodny M, Merigan TC. Journal of Clinical Microbiology. 1993; 31 (10): 2692-96
• Correlation of morphologic diagnosis of Pneumocystis carinii with the presence of pneumocystis DNA amplified by the polymerase chain reaction. Blumenfeld W, McCook O, Holodniy M, Katzenstein DA. Mod Pathol. 1992; 5 (2): 103-6
• Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. Clark AG, Holodniy M, Schwartz DH, Katzenstein DA, Merigan TC. J Acquir Immune Defic Syndr. 1992; 5 (1): 52-9
• Detection and quantification of gene amplification products by a nonisotopic automated system. Holodniy M, Winters MA, Merigan TC. Biotechniques. 1992; 12 (1): 36, 38-9
• Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. Katzenstein DA, Holodniy M, Israelski DM, Sengupta S, Mole LA, Bubp JL, Merigan TC. J Acquir Immune Defic Syndr. 1992; 5 (2): 107-12
• Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures. Winters MA, Holodniy M, Katzenstein DA, Merigan TC. PCR Methods Appl. 1992; 1 (4): 257-62
• Quantitative virological measures of antiretroviral therapy. Katzenstein DA, Holodniy M. AIDS Clin Rev. 1992: 41-67
• The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia. Mohle-Boetani J, Akula SK, Holodniy M, Katzenstein D, Garcia G. West J Med. 1992; 156 (3): 303-6
• Cerebral sparganosis: case report and review. Holodniy M, Almenoff J, Loutit J, Steinberg GK. Rev Infect Dis. 1991 Jan-Feb; 13 (1): 155-9
• Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. Holodniy M, Katzenstein DA, Sengupta S, Wang AM, Casipit C, Schwartz DH, Konrad M, Groves E, Merigan TC. J Infect Dis. 1991; 163 (4): 862-6
• Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. Mermin JH, Holodniy M, Katzenstein DA, Merigan TC. J Infect Dis. 1991; 164 (4): 769-72
• Inhibition of human immunodeficiency virus gene amplification by heparin. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. J Clin Microbiol. 1991; 29 (4): 676-9
• Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. Holodniy M, Katzenstein DA, Israelski DM, Merigan TC. J Clin Invest. 1991; 88 (5): 1755-9
• Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E. Ann Intern Med. 1990; 112 (4): 247-53
• Fulminant Kaposi's sarcoma complicating long-term corticosteroid therapy. Koop HO, Holodniy M, List AF. Am J Med. 1987; 83 (4): 787-9